Working to finalize the protocol for a potentially pivotal trial of its anti-CD3 antibody for diabetes, MacroGenics Inc. raised $45 million in a Series C round. (BioWorld Today)
Working to finalize the protocol for a potentially pivotal trial of its anti-CD3 antibody for diabetes, MacroGenics Inc. raised $45 million in a Series C round. (BioWorld Today)
With plans to expand the scope of its existing development programs, Avigen Inc. is raising $21.2 million through a private placement to institutional investors. (BioWorld Today)
